Molecular Cancer Research Genome w/Abstract AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, W.
Right arrow Articles by Marks, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, W.
Right arrow Articles by Marks, J. R.
Molecular Cancer Research 2:442-452 (2004)
© 2004 American Association for Cancer Research


Cell Cycle, Cell Death, and Senescence

TAFII70 Isoform-Specific Growth Suppression Correlates With Its Ability to Complex With the GADD45a Protein1

Wei Wang, Rita Nahta, Gudrun Huper and Jeffrey R. Marks

Department of Surgery, Duke University Medical Center, Durham, North Carolina

Requests for reprints: Jeffrey R. Marks, Department of Surgery, Duke University Medical Center, Box 3873, Durham, NC 27710. Phone: 919-681-6133; Fax: 919-681-6291. E-mail: marks003{at}mc.duke.edu

TAFII70, a member of the basal transcription complex implicated in p53-mediated transcription, is synthesized as several alternately spliced variants. The predominant forms found in normal and neoplastic breast epithelial cells are shown to be 72 kDa (TAFII70) and 78 kDa (TAFII80). Most cancers express higher levels of the TAFII80 isoform, whereas normal breast epithelia express higher levels of the TAFII70 isoform. Expression of TAFII70, but not TAFII80, causes dramatic growth suppression of normal and transformed breast epithelial cell lines in a p53-independent manner. Growth suppression correlates with mitotic inhibition resulting from an increased number of cells in G2. Both isoforms induce expression of the G2 arrest associated gene, GADD45a, but a novel protein-protein interaction was observed between TAFII70 (not TAFII80) and GADD45a, suggesting that this interaction is important for the observed growth arrest phenotype induced by the TAFII70 isoform. GADD45a null cells are not subject to TAFII70 inhibition, further supporting the relevance of this interaction.




This article has been cited by other articles:


Home page
Genes Dev.Home page
J. A. Calarco, Y. Xing, M. Caceres, J. P. Calarco, X. Xiao, Q. Pan, C. Lee, T. M. Preuss, and B. J. Blencowe
Global analysis of alternative splicing differences between humans and chimpanzees
Genes & Dev., November 15, 2007; 21(22): 2963 - 2975.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q. Chang, D. Bhatia, Y. Zhang, T. Meighan, V. Castranova, X. Shi, and F. Chen
Incorporation of an Internal Ribosome Entry Site-Dependent Mechanism in Arsenic-Induced GADD45{alpha} Expression
Cancer Res., July 1, 2007; 67(13): 6146 - 6154.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
Y. Zhang, D. Bhatia, H. Xia, V. Castranova, X. Shi, and F. Chen
Nucleolin links to arsenic-induced stabilization of GADD45{alpha} mRNA
Nucleic Acids Res., January 18, 2006; 34(2): 485 - 495.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.